May 3rd 2024
The final breast cancer screening recommendation from the United States Preventive Services Task Force advises that women aged 40 should begin biennial screening.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Steroid Mouthwash Reduces Rate and Severity of mTOR Inhibitor-Associated Stomatitis
July 19th 2016A study of women treated with the mTOR inhibitor everolimus plus exemestane for their advanced breast cancer found that daily use of an alcohol-free, steroid-based mouthwash markedly decreased the incidence and severity of stomatitis, and the researchers recommend that this preventive regimen become standard of care in this setting.
Vulnerability Tool Identifies Breast Cancer Survivors at Risk for Functional Decline
July 19th 2016Researchers from Case Western Reserve University School of Medicine and the University of Pennsylvania School of Medicine explored the use of the Vulnerable Elders Survey (VES-13) in predicting functional decline and death within 1 year of breast cancer treatment.
Kelly Kenzik Answers: Do Racial Survival Disparities Persist Long-Term?
July 14th 2016Kelly Kenzik, MS, PhD, epidemiologist at the University of Alabama at Birmingham School of Medicine, discusses her findings regarding long-term mortality disparities among African American and white women with breast cancer.
Campaign Aims to Improve Patient-Provider Communication About Metastatic Breast Cancer
July 8th 2016Although public awareness of breast cancer is generally high, this is not the case for metastatic breast cancer, and the Association of Community Cancer Centers (ACCC) is partnering with leading cancer advocacy groups on a new project to change that.
ASCO 2016: Longer Duration of AI Therapy Shows Efficacy and Preserves Quality of Life
June 6th 2016Women who extended their adjuvant therapy with an aromatase inhibitor (AI) to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.
ASCO 2016: A Research Project for Your Patients With Metastatic Breast Cancer
June 5th 2016Researchers are hoping that a new nationwide effort aimed at helping patients to share their tumor samples and clinical information will lead to new discoveries and better treatments for metastatic breast cancer.
Higher Breast Density Found in Women Who Received Hormonal Fertility Treatment
June 3rd 2016Women with a history of infertility, and have undergone hormonal fertility treatment have denser breast tissue, which may increase their risk of developing breast cancer, according to a study published in the journal Breast Cancer Research.
Disparities Found in HER2-Positive Breast Cancer Treatment in Older Women
June 2nd 2016Despite the proven effectiveness of a targeted drug for HER2-positive breast cancer, older women, especially black women, are still receiving it at low rates, according to a study conducted by researchers at the University of North Carolina at Chapel Hill (UNC) Lineberger Comprehensive Cancer Center.
Video-Based Behavioral Therapy May Ease "Chemobrain" in Breast Cancer Survivors
May 26th 2016Research suggests that 25% to 40% of individuals receiving chemotherapy experience persistent mild to moderate cognitive changes, and a study of breast cancer survivors suggests that a new type of psychotherapy delivered by videoconference may help reduce these effects, often referred to as “chemobrain.”
Nightly Fasting Found Beneficial to Reduce Breast Cancer Recurrence
May 2nd 2016A study of more than 2400 women with early-stage breast cancer has found that those who fasted 13 hours or more at night reduced their risk of breast cancer recurrence, findings that suggest prolonging the nightly fasting interval may offer a relatively safe nonpharmacologic way for women with early breast cancer to lower their risk of disease recurrence.
Comparing CVD Risk Factors Associated With Adjuvant Endocrine Therapies
May 2nd 2016A retrospective analysis conducted by researchers at Kaiser Permanente and UCLA has concluded that patients with breast cancer treated with aromatase inhibitors (AIs) as adjuvant endocrine therapy were at equal risk of serious cardiovascular disease (CVD) events as those treated with tamoxifen.
Three Prognostic Factors Found Predictive of Radiation Benefit for DCIS
April 7th 2016A team of researchers at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute has discovered a set of 3 measurable risk factors that can help predict the magnitude of survival benefit offered by radiation therapy following breast-conserving surgery for ductal carcinoma in situ.
NCCN Expert Spotlights Trials Impacting Breast Cancer Care
April 4th 2016At the 2016 NCCN Annual Conference, William J. Gradishar, MD, a professor of Breast Oncology at the Feinberg School of Medicine at Northwestern University, discussed updates to the NCCN Breast Cancer Guideline and the latest research developments in the field.